Heat decreases formoterol delivery

Chest

Volumn 128, Issue 6, 2005, Pages 4036-4040

  Robbins, Richard A ^a   Thomas, Allen R ^a   Proctor, Lynda M ^a   Hoyt, Jeffrey C ^a   Hayden, John M ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Bronchodilator; Capsule; Drug delivery; Formoterol; Heat; Powder

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; TIOTROPIUM BROMIDE;

ARTICLE; BLISTER PACK; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG STORAGE; DRY POWDER; ENVIRONMENTAL TEMPERATURE; HEAT; HEATING; POSTAL MAIL; POWDER INHALER; PRIORITY JOURNAL; SHIPPING; SUMMER;

EID: 30344440147     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.6.4036     Document Type: Article

References (7)

1. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293-304
2. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther 2003; 25:250-272
3. Foradil Aerolizer [package insert]. Kenilworth, NJ: Schering-Plough, 2002
4. Dolovich M. New delivery systems and propellants. Can Respir J 1999; 6:290-295
5. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines; American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335-371
6. Surpure JS. Heat-related illness and the automobile. Ann Emerg Med 1982; 11:263-265
7. Valenzuela TD, Criss EA, Hammargren WM, et al. Thermal stability of prehospital medications. Ann Emerg Med 1989; 18:173-176